Call for entries to Rainer Rudolph Foundation prizes

Closing date is 31 March

Young researchers who have completed an outstanding final thesis in the fields of protein biochemistry and biotechnology have another month to apply for a €1,000 Rainer Rudolph Foundation prize. Applications should be submitted to the Foundation in Germany by 31 March.

Friends, companions, former colleagues and staff of the late Professor Dr Rainer Rudolph established The Rainer Rudolph Foundation in 2011 to honour his scientific work. Prior to his death in 2009, Professor Rudolph was among the world’s leading protein biochemists as well as the co-founder of Scil Proteins, the company which now sponsors The Rainer Rudolph Foundation.


Dr Ulrike Fiedler, chief executive of the Foundation and Scil Proteins, said: ‘During his work, Professor Rudolph placed particular emphasis on linking scientific research with industrial applications and consequently, the foundation of Scil Proteins was a logical step for him. Through the years, we came to know and appreciate Professor Rudolph as a highly respected scientist and competent industrial partner. The Rainer Rudolph prizes have been established to encourage upcoming generations of scientists to excel in their work and therefore, I hope many young researchers in the fields of protein biochemistry and biotechnology will apply.’

You may also like

Manufacturing

Wacker acquires Scil Proteins Production

The transaction will create a leading microbial-based biopharmaceutical manufacturer
Ingredients

Scil Proteins receives EMA approval for commercial production of Reteplase

The recombinant protein will be produced in Halle, Germany
Research & Development

Scil Proteins signs partnership to research cancer therapies

Will work with Martin Luther University Halle-Wittenberg
Manufacturing

Anxine responds to rising demand for integrated turnkey packaging solutions

Anxine has observed that more customers are moving away from purchasing individual machines and are instead choosing complete one-stop turnkey solutions that are easier to plan, manage, and put into operation
Pharmaceutical

MHRA approves every-four-week dosing regimen for Chiesi's Elfabrio in stable adult Fabry disease patients

The firm has received MHRA approval for an additional 2 mg/kg every-four-week dosing regimen for pegunigalsidase alfa, halving the number of annual infusions required for eligible adult Fabry disease patients from 26 to 13
Regulatory

How the QA and QP Talent Market Is Changing in Pharma: Insights from Compliance Unlocked Podcast

Recruiting and retaining experienced quality and regulatory professionals has become significantly more complex for pharmaceutical and biotech companies
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Rice-ing to the occasion: how plant-based excipients are gaining ground in pharmaceutical manufacturing

As clean-label expectations migrate from health foods into pharmaceutical supply chains, natural ingredient supplier RIBUS says that rice-based excipients are becoming a credible alternative to synthetic standards
Subscribe now